Menu

Image of the Day: Not All Bad

In zebrafish, some amount of reactive oxygen species is required for normal development.

Jul 16, 2018
Sukanya Charuchandra
The eye of a zebrafish embryo with an enlarged ganglion cell layer (green)
daniel suter/purdue uNiversity

Reactive oxygen species (ROS) levels are known to rise in times of stress or disease, leading to cellular damage, even going so far as cancer. However, ROS are needed to some extent for the formation of the nervous system in zebrafish, according to a study published in The Journal of Neuroscience on June 27.

In two separate experiments, researchers used a drug and CRISPR to shut down an enzyme known to produce ROS in zebrafish embryos. With both methods, they found an absence of the enzyme, meaning fewer ROS, led to defective visual signaling and other development. 

“We think there’s an ideal intermediate concentration [of ROS], but neither extreme is good,” coauthor Daniel Suter, a professor of biological sciences at Purdue University, says in a statement.

C.J. Weaver et al., “nox2/cybb deficiency affects zebrafish retinotectal connectivity,” J Neurosci, doi:10.1523/JNEUROSCI.1483-16.2018, 2018.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.